Amit C http://www.montfordpharmacy.com . Nathwani, M.B., Ch.B., Ph.D., Ulreke M. Reiss, M.D., Edward G.D. Tuddenham, M.B., B.S., Cecilia Rosales, Ph.D., Pratima Chowdary, M.B., B.S., Jenny McIntosh, Ph.D., Marco Della Peruta, Ph.D., Elsa Lheriteau, Ph.D., Nishal Patel, F.R.C.P., F.R.C.Route., Deepak Raj, M.B., B.S., Ph.D., Anne Riddell, B.Sc., Jun Pie, B.S.N., Savita Rangarajan, M.B., B.S., David Bevan, M.B., B.S., Michael Recht, M.D., Yu-Min Shen, M.D., Kathleen G. Halka, M.D., Etiena Basner-Tschakarjan, M.D.
There was a considerably greater overall reduction from baseline with crizotinib than with chemotherapy in the symptoms of pain, dyspnea, and insomnia mainly because assessed with the use of the QLQ-C30 and in the symptoms of dyspnea, cough, upper body pain, arm or shoulder pain, and pain in other areas of your body as assessed by using the QLQ-LC13 . Patients treated with crizotinib also acquired a significantly better delay in the worsening of lung-malignancy symptoms than did patients treated with chemotherapy . A significantly better improvement from baseline was seen in EQ-5D health and wellness status ratings with crizotinib than with chemotherapy . Debate This study showed the superiority of first-line therapy with crizotinib over pemetrexed-plus-platinum chemotherapy in patients with previously untreated advanced ALK-positive NSCLC.